# US 2013/0095105 A1 · Treatment of Ocular Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0095105 A1
- Document ID: US20130095105A1
- Status: Published application
- Kind: A1
- Application number: 13/652,154
- Filed: 2012-10-15
- Published: 2013-04-18
- Earliest claimed: 2011-10-13
- Assignees: Aerpio Therapeutics Inc.
- Inventors: Kevin Peters; Robert Shalwitz
- Web page: https://patentgrep.com/patent/US20130095105A1

## CPC

- C07K 16/40: against enzymes
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61P 27/02: Ophthalmic agents
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

## Claims

### Claim 1

A method for treating or preventing an ocular disorder comprising administering to a subject a composition comprising an effective amount of an HPTPβ-ECD binding agent or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the ocular disorder is ocular neovascularization, ocular edema, retinal edema, retinal neovascularization, diabetic retinopathy, diabetic macular edema, age-related macular degeneration, choroidal neovascularization, central retinal vein occlusion, branch retinal vein occlusion, ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, non-proliferative retinopathy, retinal angiomatous proliferation, macular telangiectasia or uveitis.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the ocular disorder is retinal edema.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the ocular disorder is retinal neovascularization.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the ocular disorder is diabetic retinopathy.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the ocular disorder is diabetic macular edema.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the dose of the HPTPβ-ECD binding agent, or a pharmaceutically acceptable salt thereof, administered to the subject is from about 0.01 mg/kg to about 10 mg/kg by weight of the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dose is administered once daily, three-times weekly, twice weekly, once weekly, three times monthly, twice monthly, once monthly, or once every other month.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the HPTPβ-ECD binding agent is an antibody, a protein, a peptide, an aptamer, a peptibody, an adnectin, or a nucleic acid, that binds to the extracellular portion of HPTPβ.

### Claim 11 (depends on 10)

The method according claim 10, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen binding fragment thereof, or a polyclonal antibody, or antibody or antigen binding fragment thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the dose is administered once daily, three-times weekly, twice weekly, once weekly, three times monthly, twice monthly, once monthly, and once every other month.

### Claim 13 (depends on 11)

The method according claim 11, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen binding fragment thereof.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the HPTPβ-ECD binding agent is an antigen binding fragment of an antibody, wherein the antigen binding fragment is an F(ab′)2, an Fab, dimer of an Fab, an Fv, dimer of an Fv, or dimer of a scFv.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the HPTPβ-ECD binding agent is an antigen binding fragment of an antibody, wherein the antigen binding fragment is an F(ab′)2, a dimer of an Fab, a dimer of an Fv, or a dimer of a scFv.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the HPTPβ-ECD binding agent is the monoclonal antibody produced by hybridoma cell line ATCC No. PTA-7680 or an antigen binding fragment thereof.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the HPTPβ-ECD binding agent has the same or substantially the same biological characteristics as the monoclonal antibody produced by hybridoma cell line ATCC No. PTA-7680 or an antigen binding fragment thereof.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the HPTPβ-ECD binding agent is conjugated to a vehicle.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the vehicle is PEG.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the HPTPβ-ECD binding agent is administered by intraocular injection, subcutaneous injection or intravenous injection.
